Abstract
During the pathology of atherosclerosis and restenosis, hyperproliferation and migration of vascular smooth muscle cells (VSMC) contribute to lumen loss of the vessel and neointima formation [1]. Drugs interfering with both, proliferation and migration of VSMC are therefore promising candidates for the treatment of vasculoproliferative diseases.